Correction: Intravenous tirofiban therapy for patients with capsular warning syndrome

Li W, Wu Y, Li X, *et al.* Intravenous tirofiban therapy for patients with capsular warning syndrome. *Stroke Vasc Neurol* 2019. doi: 10.1136/svn-2018-000163. [Epub ahead of print 9 Jan 2019].

In the Results section of the Abstract, “After treatment, in T-group, four patients (26.7%) had recurrent attacks, and NIHSS scores were in 11 patients (73.3%) at 24 hours” should read “After treatment, in T-group, four patients (26.7%) had recurrent attacks, and NIHSS scores were 0 in 11 patients (73.3%) at 24 hours.”

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Stroke and Vascular Neurology 2019;4:e000163corr1. doi:10.1136/svn-2018-000163corr1